Spots Global Cancer Trial Database for Precision Medicine for Every Child With Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Precision Medicine for Every Child With Cancer
Official Title: Precision Medicine for Every Child With Cancer
Study ID: NCT05504772
Study Description
Brief Summary: To improve outcomes for childhood cancer patients through the implementation of precision medicine.
Detailed Description: Through the pilot TARGET and national PRISM trials the feasibility and benefits of using comprehensive molecular profiling and preclinical drug testing in real time for high-risk (HR) patients has been demonstrated. However, the role of precision medicine, especially in facilitating diagnosis and risk stratification in non-HR childhood cancers has not been studied. Integrative tumor-germline whole genome sequencing (WGS) analysis has the potential to advance our understanding of cancer predisposition. In this study, the ZERO platform will be extended to all children with cancer in Australia and New Zealand, evaluating the benefits of precision medicine in different childhood cancer types and risk groups.
Eligibility
Minimum Age: 0 Years
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Women's and Children's Hospital, Adelaide, , Australia
Queensland Children's Hospital, Brisbane, , Australia
Royal Hobart Hospital, Hobart, , Australia
Monash Children's Hospital, Melbourne, , Australia
Royal Children's Hospital, Melbourne, , Australia
John Hunter Children's Hospital, Newcastle, , Australia
Perth Children's Hospital, Perth, , Australia
Sydney Children's Hospital, Randwick, Sydney, , Australia
The Children's Hospital at Westmead, Sydney, , Australia
Contact Details
Name: David Ziegler
Affiliation: SCHN
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
